Who Paid My Doc
Amanda Fernandes
Endocrinology, Diabetes & Metabolism Riverside, RI Medical Doctor
NPI 1649602863 CMS profile 6734609
375 Wampanoag Trl, Ste 202B, Riverside, RI 02915
General payments
$147
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$28,256
Through program year 2023, Amanda Fernandes of Riverside, RI is reported in the CMS Open Payments database as having received $147 across 2 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $28,256 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 17th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $22 | 1 | |
| 2021 | General | $125 | 1 |
Beside peers
- Amanda Fernandes
- Endocrinology, Diabetes & Metabolism median
- Middle half of Endocrinology, Diabetes & Metabolism
- National median
In program year 2025, general payments to Amanda Fernandes were reported at $0. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.
Show as a table
| Year | Amanda Fernandes | Endocrinology, Diabetes & Metabolism median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $494 | $123–$2,253 | $163 |
| 2020 | $0 | $335 | $85–$1,841 | $114 |
| 2021 | $125 | $398 | $88–$1,981 | $132 |
| 2022 | $0 | $364 | $88–$1,568 | $149 |
| 2023 | $22 | $420 | $113–$1,614 | $160 |
| 2024 | $0 | $440 | $121–$1,646 | $164 |
| 2025 | $0 | $507 | $135–$1,838 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 42 drugsPart D claims
2,393
Drug cost
$1,016,115
Branded share of claims
64.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 268 | $267,735 | |
| Jardiance Empagliflozin | Brand | 230 | $209,655 | |
| Trulicity Dulaglutide | Brand | 175 | $179,144 | |
| Mounjaro Tirzepatide | Brand | 94 | $97,867 | |
| Humulin R U-500 Kwikpen Insulin Regular, Human | Brand | 46 | $88,845 | |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | Brand | 87 | $37,033 | |
| Farxiga Dapagliflozin Propanediol | Brand | 27 | $24,241 | |
| Januvia Sitagliptin Phosphate | Brand | 15 | $15,220 | |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 124 | $14,531 | |
| Humalog Kwikpen U-100 Insulin Lispro | Brand | 53 | $10,693 |
The 10 drugs with the highest cost, of 42 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 13 billing codesPaid by Medicare
$29,717
Medicare patients
173
Services billed
419
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 52% | |
| Arthritis | 52% | |
| Chronic kidney disease | 36% | |
| Osteoporosis | 35% | |
| Ischemic heart disease | 32% | |
| Depression | 28% | |
| Heart failure | 24% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Endocrinology, Diabetes & Metabolism in Rhode Island
Robert Dobrzynski
Endocrinology, Diabetes & Metabolism · Providence, RI
Frank D'alessandro
Endocrinology, Diabetes & Metabolism · North Providence, RI
Ricardo Correa Marquez
Endocrinology, Diabetes & Metabolism · East Providence, RI
Robert Smith
Endocrinology, Diabetes & Metabolism · Providence, RI
Sudhir Bansal
Endocrinology, Diabetes & Metabolism · Warwick, RI
Joseph Tucci
Endocrinology, Diabetes & Metabolism · Providence, RI
Related records
Endocrinology, Diabetes & Metabolism in Rhode Island
Practitioners in the same specialty and state, ranked by reported value.
All Endocrinology, Diabetes & Metabolism
Everyone recorded under this specialty, nationwide.
Doctors in Rhode Island
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.